Get the Stockscreener App
0.6231
2.99%
0.0181
Atossa Therapeutics Inc stock is traded at $0.6231, with a volume of 415.12K.
It is up +2.99% in the last 24 hours and down -14.67% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$0.605
Open:
$0.6
24h Volume:
415.12K
Relative Volume:
0.65
Market Cap:
$81.96M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-2.8323
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
+5.66%
1M Performance:
-14.67%
6M Performance:
-57.03%
1Y Performance:
-53.84%
1-Day Range:
$0.5914
$0.63
1-Week Range:
$0.5897
$0.674
52-Week Range:
$0.5526
$1.81
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.6231 | 81.96M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Atossa Therapeutics (ATOS) Partners with Nona Biosciences to Adv - GuruFocus
Nona Biosciences and Atossa Therapeutics Partner to Discover Nex - GuruFocus
Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - The Manila Times
Revolutionary Breast Cancer Treatment Alliance: Next-Gen Antibody Platform Powers New Research Initiative - Stock Titan
Atossa Therapeutics (NASDAQ:ATOS) & Pharming Group (OTCMKTS:PHGUF) Critical Comparison - Defense World
Atossa Therapeutics says Intas Pharmaceuticals Filed Petition For Post Grant Review Against Co- SEC Filing - marketscreener.com
Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress - MSN
Charles Schwab Investment Management Inc. Lowers Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Monday - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Q4 2024 Earnings Call Transcript - Insider Monkey
Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock By Investing.com - Investing.com Canada
Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst - Defense World
Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock - Investing.com India
All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy - Yahoo Finance
Atossa Therapeutics (NASDAQ:ATOS) Earns Buy Rating from HC Wainwright - Defense World
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Yahoo
Atossa Therapeutics Inc (ATOS) Q4 2024 Earnings Call Highlights: - GuruFocus
Atossa Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Atossa Therapeutics’ Strategic Focus on Z-endoxifen for Breast Cancer Drives Buy Rating - TipRanks
Earnings call transcript: Atossa Genetics Q4 2024 beats EPS forecast - Investing.com
Atossa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Atossa Therapeutics Inc Reports Q4 EPS of -$0.06, Aligning with Estimates; Revenue Remains at $0 Million - GuruFocus
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
Earnings Scheduled For March 25, 2025 - Benzinga
Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Tuesday - Defense World
Atossa Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Atossa Therapeutics to Host Conference Call for Q4 and Full-Year 2024 Financial Results on March 25, 2025 - Nasdaq
Atossa Therapeutics Earnings: Key Q4 and 2024 Results Coming March 25How to Listen Live - StockTitan
Atossa Therapeutics (NASDAQ:ATOS) Given “Buy” Rating at HC Wainwright - The AM Reporter
HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World
Atossa Genetics stock hits 52-week low at $0.7 amid market challenges - Investing.com Australia
Atossa Genetics stock hits 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa
Nothing is Better Than Atossa Therapeutics Inc (ATOS) stock at the moment - SETE News
Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - TradingView
Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen - TipRanks
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications - The Manila Times
Breakthrough: New Breast Cancer Drug Shows 3x Better Survival Rate Than Standard Treatment - StockTitan
Atossa targets metastatic breast cancer with (Z)-endoxifen - Investing.com
Atossa Genetics stock hits 52-week low at $0.72 - Investing.com
Atossa Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com South Africa
Atossa Therapeutics faces Nasdaq delisting over bid price - Investing.com
Atossa Therapeutics reports progress in breast cancer treatments - MSN
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 5.8% in January - MarketBeat
Atossa Therapeutics Inc (ATOS) looking to reclaim success with recent performance - SETE News
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):